AGT and triple-A syndrome: Notably, CL316,243 administration significantly reduced AAA incidence (76.5% vs 16.7%, Fig. 1J) and decreased the maximal diameter of the abdominal aorta compared with saline control after Ang II infusion, as indicated by ex vivo analyses and ultrasound imaging (Fig. 1K–M).